Non-promoter hypermethylation of zygote arrest 1 (ZAR1) in human brain tumors
Tóm tắt
Zygote arrest 1 (ZAR1) is a novel maternal-effect gene of crucial importance during the oocyte-to-embryo transition. Comprehensive methylation analysis of tumor-specific differently methylated regions in human malignant melanomas has recently led to the identification of non-promoter hypermethylation of the ZAR1 gene that had never been identified as an aberrant methylated region in any human tumor. Notably, ZAR1 hypermethylation was frequently observed in melanomas but was absent in benign nevi, and ZAR1 expression was found to be up-regulated in methylated tumors. These findings prompted us to screen for ZAR1 non-promoter methylation in various types of human brain tumors using MassARRAY EpiTYPER. Strikingly, hypermethylation of ZAR1 was observed frequently in diffuse astrocytomas (100%), anaplastic astrocytomas (94%), glioblastomas (93%), oligodendrogliomas (100%), anaplastic oligodendrogliomas (100%), and pituitary adenomas (90%), but not at all in pilocytic astrocytomas. For other tumor types ZAR1 hypermethylation was infrequent: 17% of vestibular schwannomas and 33% of meningothelial meningiomas. Detectable ZAR1 transcript was not found in any of hypermethylated glioma cell lines. Our results indicate that hypermethylation of the ZAR1 non-promoter is extremely frequent in diffuse gliomas and pituitary adenomas, although ZAR1 expression is unlikely to play a tumorigenic role.
Tài liệu tham khảo
Mueller W, Nutt CL, Ehrich M et al (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26:583–593
Nakamura M, Watanabe T, Klangby U et al (2001) p14 ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168
Nakamura M, Yonekawa Y, Kleihues P et al (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81:77–82
Nakamura M, Watanabe T, Yonekawa Y et al (2001) Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715–1719
Ohta T, Watanabe T, Katayama Y et al (2006) Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas. Oncol Rep 16:957–963
Watanabe T, Yokoo H, Yokoo M et al (2000) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189
Watanabe T, Katayama Y, Komine C et al (2005) O 6-Methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113:581–587
Ehrich M, Nelson MR, Stanssens P et al (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102:15785–15790
Shinojima Y, Terui T, Kimura M et al (2010) Identification and analysis of an early diagnostic marker for malignant melanoma: ZAR1 intra-genic differentially methylated region. J Dermatol Sci 59:98–106
Wu X, Viveiros MM, Eppig JJ et al (2003) Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to-embryo transition. Nature Genet 33:187–191
Watanabe T, Yachi K, Ohta T et al (2010) Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors. Neurol Med Chir (Tokyo) 50:1062–1069
Watanabe T, Katayama Y, Yoshino A et al (2007) Aberrant hypermethylation of p14 ARF and O 6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17:5–10
Yan H, Parsons W, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. New Eng J Med 360:765–773
Smith JF, Mahmood S, Song F et al (2007) Identification of DNA methylation in 3′ genomic regions that are associated with upregulation of gene expression in colorectal cancer. Epigenetics 2:161–172